NCT05903430
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
Recruiting · Not specified · The Christie NHS Foundation Trust · registry updated 2025-09-05
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
Inclusion
- Have no MRI contra-indications.
- Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines.
- Be able to give informed consent.
- Anticipated life-expectancy \> 6 months.
- Not more than 3 oligmetastatic sites treated in total per patients.
- Performance status ≤ 2.
Exclusion
- Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
- Unable to tolerate MRI scans.
- Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study.
- Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.
- Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).